Vorinostat, an HDAC inhibitor suppressing HIF-1α by modulating its translocation [98], is currently in clinical trials for patients with breast cancer (NCT01720602, NCT03742245, NCT04190056). This evidence concerns the gene HIF1A and breast carcinoma.